Product Data Sheet

Azithromycin

Cat. No.: HY-17506 CAS No.: 83905-01-5 Molecular Formula: $C_{38}H_{72}N_2O_{12}$ Molecular Weight: 748.98

Target: Bacterial; Autophagy; Antibiotic; Parasite

Pathway: Anti-infection; Autophagy

Storage: Powder -20°C 3 years

2 years

In solvent -80°C 2 years

> -20°C 1 year

SOLVENT & SOLUBILITY

In Vitro DMSO : ≥ 100 mg/mL (133.51 mM)

* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	1.3351 mL	6.6757 mL	13.3515 mL
	5 mM	0.2670 mL	1.3351 mL	2.6703 mL
	10 mM	0.1335 mL	0.6676 mL	1.3351 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (3.34 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 2.5 mg/mL (3.34 mM); Suspended solution; Need ultrasonic
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (3.34 mM); Clear solution

BIOLOGICAL ACTIVITY

Description	Azithromycin is a macrolide antibiotic useful for the treatment of a number of bacterial infections.	
IC ₅₀ & Target	Macrolide	
In Vitro	Azithromycin (2 μM) augments rhinovirus-induced IFNβ expression in primary bronchial epithelial cells from asthmatics, which is associated with over-expression of RIG-I like receptors and repression of viral replication. Knockdown of MDA5, but	

not knockdown of RIG-I, diminishes azithromycin (2 μ M)-enhanced viral-induced IFN β expression in asthmatic primary bronchial epithelial cells^[1]. Azithromycin specifically reduces MMP-9 mRNA and protein levels without affecting NF- κ B in endotoxin-challenged monocytic THP-1 cells^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Azithromycin (50 mg/kg) has no effect on bronchoalveolar lavage inflammatory parameters and LDH levels in a mouse model of asthma exacerbation. Azithromycin induces neither general inflammatory parameters nor LDH release in a mouse model of asthma exacerbation, and augments expression of interferon-stimulated genes and the pattern recognition receptor MDA5 but not RIG-I in exacerbating mice^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Cell Assay [2]

THP-1 cells (10^6 cells in 1 mL RPMI medium, without antibiotics, growth factors or serum) are seeded in each well of 24-well plates and allowed to settle for 1 hour. Next, 50 μ L of the test compound is added followed by 50 μ L of LPS (final concentration of 10 μ g/mL). After 24h (37°C and 5% CO₂) the supernatants and cell pellets are collected (1200 rpm, 5 min). THP-1 cell viability is tested using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). MTT is dissolved at 2 mg/mL in PBS and aliquots are stored at -20°C. The MTT assay is performed according to the suppliers instructions. Absorbance of MTT converted into formazan is measured at a wavelength of 570 nm with background subtraction at 630 nm. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Adv Sci (Weinh). 2020 Jul 21;7(17):2001374.
- Acta Pharm Sin B. 2021 Mar 11.
- Emerg Microbes Infect. 2024 Dec;13(1):2321981.
- Mol Ther. 2022 Feb 18;S1525-0016(22)00102-2.
- Theranostics. 2022 Jan 1;12(3):1187-1203.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Menzel M, et al. Azithromycin augments rhinovirus-induced IFNβ via cytosolic MDA5 in experimental models of asthma exacerbation. Oncotarget. 2017 Mar 18.

[2]. Vandooren J, et al. Differential inhibition of activity, activation and gene expression of MMP-9 in THP-1 cells by azithromycin and minocycline versus bortezomib: A comparative study. PLoS One. 2017 Apr 3;12(4):e0174853.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA